Femasys Secures European Approval for FemBloc®
June 26, 2025
First-Ever Non-Surgical Permanent Birth Control System Gains CE Mark, Paving the Way for a New Era in Reproductive Health
First-Ever Non-Surgical Permanent Birth Control System Gains CE Mark, Paving the Way for a New Era in Reproductive Health
Breakthrough Integrated Sacral Neuromodulation Device Approved to Treat Urinary Urge Incontinence with a Minimally Invasive, Patient-Centric Approach
Lilli Health, a company that coined the term Low Insulin Lifestyle [LILLI] created to help educate, treat and manage individuals with polycystic ovary syndrome (PCOS), has announced the launch of the Lilli App backed by decades of scientific research as the first-ever comprehensive platform focused on lowering insulin levels to reverse PCOS symptoms.
A new point of care test for pre-eclampsia is set to revolutionise testing for suspected pre-eclampsia in maternity units across the UK, aiding early detection and prognosis in pregnant women between 20-37 weeks of gestation.
SAN JOSE, Calif., June 18, 2025 /PRNewswire/ — Neuspera® Medical, Inc., the leading developer of integrated technologies powering the future of neuromodulation, today announced that the U.S. Food and Drug Administration (FDA) has approved its integrated sacral neuromodulation (iSNM) system for the treatment of urinary urge incontinence (UUI).
The BiophysicaL Immune Profiling for Infants (BLIPI) profiles an infant’s immune system in under 15 minutes, using just a single drop of blood.
Researchers at the University of California, Davis, have developed an investigational brain-computer interface that holds promise for restoring the voices of people who have lost the ability to speak due to neurological conditions.
A team of scientists and biomedical engineers developing pioneering technology designed to treat threatened miscarriage has secured 1 million GBP in Invention for Innovation (i4i) funding from the National Institute for Health and Care Research (NIHR) for its first clinical trial.
Mediplus has announced the release of new sizes of the POPY (Pelvic Organ Prolapse pessary) product range. The company is introducing five additional sizes to complement its existing products, offering a more precise fit and enhanced treatment options for women suffering from pelvic organ prolapse.
IceCure has 20+ patents in the U.S. and the Company anticipates further market traction upon FDA’s marketing authorization decision in early-stage breast cancer